• Menu
    • Search
    • Stock Code: 00512.HK
    • About Us
      • Company Profile
      • Company History
      • Enterprise Members
    • Product Center
      • Pharmaceutical Preparations and Medical Devices
      • Bio-technology Products and Health Products
      • Specialized Pharmaceutical Raw Materials and Other Products
      • Innovative Pipeline
    • Investor Relations
      • Information Disclosure
      • Corporate Governance
      • Stock Info
      • Contact Information
    • News & Media
      • Corporate News
      • Media Reports
    • Contact Us
      • Contact Information
      • Privacy Protection
    • Language
      • EnglishEnglish
      • 繁体中文繁体中文
      • 简体中文简体中文
  • English English
    • EnglishEnglish
    • 繁体中文繁体中文
    • 简体中文简体中文
  • Stock Code: 00512.HK

News Center

  • Home
  • News Center
  • Show All
  • Corporate News
  • Media Reports
Grand Pharma Reaches Strategic Cooperation with Eye Hospital, WMU, Strategically Planning the New Ophthalmic Preparation, And Building Public Eye Protection Ecosystem

Grand Pharma Reaches Strategic Cooperation with Eye Hospital, WMU, Strategically Planning the New Ophthalmic Preparation, And Building Public Eye Protection Ecosystem

2022-5-25 Corporate News READ MORE
Grand Pharma’s Global Innovative Product STC3141 Approved for Phase Ib Clinical Study in Belgium, Another Milestone of Global Innovative Products and Continues the Globalization Development Process

Grand Pharma’s Global Innovative Product STC3141 Approved for Phase Ib Clinical Study in Belgium, Another Milestone of Global Innovative Products and Continues the Globalization Development Process

2022-4-26 Corporate News READ MORE
The Phase III Clinical Trial in China of Grand Pharma’s Global Innovative Drug Ryaltris Compound Nasal Spray Successfully Completed the First Patient Enrollment, Milestone Progress in the Landing Process of Innovative Products and Continuously Consolidating Core Competitiveness in Pharmaceutical Industry

The Phase III Clinical Trial in China of Grand Pharma’s Global Innovative Drug Ryaltris Compound Nasal Spray Successfully Completed the First Patient Enrollment, Milestone Progress in the Landing Process of Innovative Products and Continuously Consolidating Core Competitiveness in Pharmaceutical Industry

2022-4-7 Corporate News READ MORE
Grand Pharma Announces 2021 Annual Results, Profit Attributable to Owners of the Company Increase 34.0% to HK$2,402.6 million, Continuing to Deepen the Strategic Plan of Global Technological Innovation, Multiple Products will be Lunched Successively to Provide Long-term Momentum

Grand Pharma Announces 2021 Annual Results, Profit Attributable to Owners of the Company Increase 34.0% to HK$2,402.6 million, Continuing to Deepen the Strategic Plan of Global Technological Innovation, Multiple Products will be Lunched Successively to Provide Long-term Momentum

2022-3-18 Corporate News READ MORE
Grand Pharma Entered into an Equity Investment Agreement with ITM in Germany, Further Consolidate the Group’s Comprehensive Industrial Chain Layout in Research, Production and Commercialization of Radionuclides

Grand Pharma Entered into an Equity Investment Agreement with ITM in Germany, Further Consolidate the Group’s Comprehensive Industrial Chain Layout in Research, Production and Commercialization of Radionuclides

2022-2-16 Corporate News READ MORE
Grand Pharma’s Global Innovative Radiopharmaceutical Drugs SIR-Spheres® Y-90 Microsphere Injection Were Approved for Commercialization by NMPA in China, For The Treatment of Colorectal Cancer Liver Metastases

Grand Pharma’s Global Innovative Radiopharmaceutical Drugs SIR-Spheres® Y-90 Microsphere Injection Were Approved for Commercialization by NMPA in China, For The Treatment of Colorectal Cancer Liver Metastases

2022-2-9 Corporate News READ MORE
GP (HK) Entered into an Exclusive Product Licensing Agreement with ITM in Germany, Strategically Plans Three Global Innovative RDC Drugs, Significant Milestone in the Field of Radionuclide Drugs

GP (HK) Entered into an Exclusive Product Licensing Agreement with ITM in Germany, Strategically Plans Three Global Innovative RDC Drugs, Significant Milestone in the Field of Radionuclide Drugs

2021-12-27 Corporate News READ MORE
GP (HK)’s Global Innovative RDC Drug TLX591-CDX Was Approved in The United States, Another Milestone Progress of the Group’s Innovative Products’ Commercialization

GP (HK)’s Global Innovative RDC Drug TLX591-CDX Was Approved in The United States, Another Milestone Progress of the Group’s Innovative Products’ Commercialization

2021-12-21 Corporate News READ MORE
GP (HK)’s Global Innovative Drug STC3141 Successfully Completed the Enrolment and Dosing of All Patients in Phase IIa Clinical Trial for COVID-19 in Europe, Another Milestone in Global Clinical Trial, and Consolidating the Strategic Plan in the Field of Severe Anti-infection

GP (HK)’s Global Innovative Drug STC3141 Successfully Completed the Enrolment and Dosing of All Patients in Phase IIa Clinical Trial for COVID-19 in Europe, Another Milestone in Global Clinical Trial, and Consolidating the Strategic Plan in the Field of Severe Anti-infection

2021-12-14 Corporate News READ MORE
GP (HK) Introduces A Global Innovative Mitral Valve Replacement Medical Device – Saturn, Continue To Deepen The Product Pipeline Strategic Plan In The Field Of Precision Interventional Diagnosis And Treatment

GP (HK) Introduces A Global Innovative Mitral Valve Replacement Medical Device – Saturn, Continue To Deepen The Product Pipeline Strategic Plan In The Field Of Precision Interventional Diagnosis And Treatment

2021-11-28 Corporate News READ MORE
GP (HK)’s Global Innovative Drug STC3141 Successfully Dosed the First Patient of its Phase Ib Clinical Trial for ARDS In China, Deepen the Dual-Cycle Development Strategy and Continues the Global Development Process

GP (HK)’s Global Innovative Drug STC3141 Successfully Dosed the First Patient of its Phase Ib Clinical Trial for ARDS In China, Deepen the Dual-Cycle Development Strategy and Continues the Global Development Process

2021-11-10 Corporate News READ MORE
GP (HK)’s Global Innovative Drug Ryaltris Compound Nasal Spray Has Been Granted Phase Three Clinical Trial Approval, Enriches the Group’s Product Pipeline, and Consolidates its Competitive Advantage in the field of Respiratory & ENT

GP (HK)’s Global Innovative Drug Ryaltris Compound Nasal Spray Has Been Granted Phase Three Clinical Trial Approval, Enriches the Group’s Product Pipeline, and Consolidates its Competitive Advantage in the field of Respiratory & ENT

2021-10-21 Corporate News READ MORE
Yuanda medicine gets sepsis innovative medicine again

Yuanda medicine gets sepsis innovative medicine again

2020-3-31 Media Reports READ MORE
Page 1 of 512345»
Contact Us

Units 3302, 33/F, The Center, 99 Queen's Road Central, Hong Kong

ir@grandpharm.com

www.grandpharm.com

Pages Links

Company Profile

Product Center

Investor Relations

News & Media

Stock Info

Contact Us

Privacy

Legal Statement

Recent News
  • Grand Pharma Reaches Strategic Cooperation with Eye Hospital, WMU, Strategically Planning the New Ophthalmic Preparation, And Building Public Eye Protection Ecosystem

    2022-5-25

  • Grand Pharma’s Global Innovative Product STC3141 Approved for Phase Ib Clinical Study in Belgium, Another Milestone of Global Innovative Products and Continues the Globalization Development Process

    2022-4-26

© 2022. Grand Pharmaceutical Group Limited All Rights Reserved.